|
Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects. Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects. conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects. Clinical research trials and Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects. healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.. Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects. Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects. clinical trial. Subjects frequently obtain the most expert healthcare possible for their Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects. condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.  Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.
Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.
For Condition: Bacterial Infections,HIV Infections
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.
Details: Patients are randomized to receive azithromycin orally or intravenously, with crossover to the alternate treatment after a 21-day wash-out period.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Antiretroviral agents, provided regimen has been stable for at least 1 month. Patients must have: - HIV infection. - CD4 count <= 200 cells/mm3. - No active opportunistic infection (pending discussion with Pfizer Clinician). Prior Medication: Allowed: - Prior antiretroviral agents. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Active intercurrent illness (pending discussion with the Pfizer Clinician). - Allergies to macrolide antibiotics. - Signs and symptoms of severe illness that would preclude treatment. Patients with the following prior conditions are excluded: - History of clinically significant allergic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease. - Clinically important change in baseline status within 4 weeks prior to study entry. - Condition affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies) within 4 weeks prior to study entry. Prior Medication: Excluded: - Investigational drugs including treatment IND drugs within 4 weeks prior to study entry. Known drug or alcohol dependence.
Total Enrollment:
Location and Contact Information:
Ctr for Phase I Research
Wichita, Kansas, 67214
United States
Additional Information:
Study ID Numbers: 226D; 066-062
Study Start Date:
Record last reviewed: April 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002139
Other Hiv Infections Studies:
1. Antibiotic treatment for patients with infections of short term in-dwelling vascular catheters due to a specific bacteria (gram positive bacteria)
2. New antibiotic to treat pediatric patients with infections due to a specific bacteria (Vancomycin-Resistant Enterococcus)
3. A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
4. Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis
5. Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines
Related Studies:
Other HIV Infections Clinical Trials
Other Kansas Clinical Trials
Other Wichita Clinical Trials
Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.
|
|
|
|
|
|
|
|
